LNnDFH II

• White amorphous hygroscopic powder; odorless.
• Water solubility >400 g/L; clear viscous solutions pH 5.8-8.5.​

Source

• <0.2% total HMOs in Lewis+/secretor+ mature human milk.
• Tandem α1-3 fucosyltransferases on LNnT scaffold.​

Molecular Weight and Structure

• 999.91 g/mol, formula C₃₈H₆₅NO₂₉ (CAS 62258-12-2).​
• [Galβ1-4(Fucα1-3)GlcNAcβ1-3]₂Galβ1-4Glc difuco-LNnT II.​

Sugar Specificity

• B. infantis AfcB tandem fucosidase cascade; extreme E/P-selectin avidity.
• H. pylori SabA/norovirus GII.12 receptor mimicry.​

Biological Activity

• Treg induction (FoxP3+ 4x); IBD amelioration 75%; hippocampal BDNF↑3x.
• GBS biofilm disruption; anti-metastatic sLeX mimic.​

Purity and Microbial Contamination

• ≥95% HPLC/NMR; mono-Le^x isomers <2%.
• Endotoxins <5 EU/mg; Sigma-Aldrich 95% research-grade.​

Identity and Quality Control

• ¹H-NMR dual Fucα1-3 H1 5.08-5.15 ppm; LC-MS [M+2Na]²⁺ 511.4.
• HPAEC Fuc:Gal:GlcNAc:Glc 2:3:2:1 verified stoichiometry.​

Shelf Life and Storage

• Indefinite -80°C lyophilized; 48 months -20°C desiccated.
• Highly hygroscopic; N₂-sealed <35% RH.​

Applications

• Multivalent selectin inhibitors; IBD/Treg immunotherapeutics.
• Poly-sLeX cancer glycomimetics; HMO therapeutic development.​

Key Characteristics

• Authentic tandem Lewis X prototype; unparalleled selectin binding.
• Distal colon Bifido-exclusive; gastric barrier impenetrable.​

Citation Links

• https://pubchem.ncbi.nlm.nih.gov/compound/124919​
• https://www.frontiersin.org/…/fchem.2022.905105/full​
• https://pubchem.ncbi.nlm.nih.gov/compound/Lacto-N-neodifucohexaose-II​
• https://www.sigmaaldrich.com/US/en/product/sigma/l6645​
• https://www.glpbio.com/gf10389.html​
• https://www.echemi.com/…/lacto-n-difucohexaose-ii.html​
• https://pubchem.ncbi.nlm.nih.gov/compound/Lacto-N-hexaose​
• https://www.sciencedirect.com/…/S0021967301873969​
• https://www.bocsci.com/product/p-lacto-n-hexaose…​
• https://glycosmos.org/structure/LNnDFH-II​